Deutsche Bank
CLYM

Deutsche Bank’s Climb Bio CLYM Stock Holding History

Deutsche Bank’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Hold
1
– – ﹤0.01% 3614
2025
Q4 		$4 Hold
1
– – ﹤0.01% 3617
2025
Q3 		$2 Sell
1
-12,381
-100% -$23K ﹤0.01% 3600
2025
Q2 		$15.4K Buy
+12,382
New +$15.4K ﹤0.01% 3495
2022
Q2 		– Sell
-3,841
Closed -$32K – 4357
2022
Q1 		$32K Sell
3,841
-452
-11% -$4.22K ﹤0.01% 3966
2021
Q4 		$45K Buy
4,293
+230
+6% +$3.43K ﹤0.01% 3983
2021
Q3 		$73K Buy
+4,063
New +$83.9K ﹤0.01% 4019

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Deutsche Bank's CLYM Position: Q1 2026 in Review

Deutsche Bank held its Climb Bio (CLYM) position steady in Q1 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Deutsche Bank first reported a position in CLYM in Q3 2021 and has held it in 7 quarters since. The position peaked at $73K in Q3 2021. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Deutsche Bank held 1 share of Climb Bio worth $7 as of Q1 2026.
  • Deutsche Bank left its Climb Bio share count unchanged in Q1 2026.
  • Climb Bio made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3614 holding.
  • Deutsche Bank first reported a position in Climb Bio in Q3 2021 and has held it in 7 quarters since.
  • Deutsche Bank's Climb Bio position peaked at $73K in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.